07.03.2013 - German Alzheimer specialist Probiodrug AG has widened its management team by two new positions. Ronald Black will take over as Chief Medical Officer, while Inge Lues has been appointed Chief Development Officer.
Before joining Probiodrug, Black held various senior research roles at Pfizer and at Wyeth Pharmaceuticals prior to its acquisition by Pfizer. Most recently he was the assistant vice president of the firm's Alz-heimer immunotherapy programme. The native of the US has been involved with two New Drug Applications and eight Investigational New Drug filings, and has authored more than 40 publications. From 2008 until joining Probiodrug, Inge Lues acted as an R&D adviser to venture capital and biotechnology companies. During this period, she helped Probiodrug identify drug candidates and advance them into clinical studies. Previously the physiologist was the Executive Vice President Global Drug Discovery and Non-clinical Development at German Merck KGaA (Darmstadt).